Aug 27, 2026 09:01AM

Aug 27, 2026 09:00AM

Jun 4, 2026 08:03AM

Jun 4, 2026 08:00AM

Mar 12, 2026 08:32AM

Mar 12, 2026 08:30AM

Mar 10, 2026 08:31AM Celularity secures $35 million licensing deal for biomaterials portfolio

Mar 10, 2026 08:30AM

Dec 5, 2025 04:40PM

Oct 14, 2025 08:45AM

Oct 14, 2025 08:45AM

Jul 9, 2025 08:30AM

Jul 1, 2025 08:30AM

May 9, 2025 09:15AM Celularity Announces Full Year 2024 Operating and Financial Results

Feb 25, 2025 08:00AM

Oct 22, 2024 08:31AM

Oct 22, 2024 08:30AM

Mar 20, 2024 09:15AM

Mar 20, 2024 09:15AM

Feb 1, 2024 09:00AM

Oct 18, 2023 09:03AM Celularity (CELU) Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product Classification

Apr 12, 2023 09:00AM

Apr 3, 2023 09:05AM

Apr 3, 2023 09:00AM

Feb 2, 2023 07:53AM

Feb 1, 2023 04:06PM

Feb 1, 2023 04:05PM

Jan 26, 2023 04:17PM Celularity Completes Strategic Review of 2023 Initiatives, Including Anticipated Biomaterials Production Ramp-Up and Pipeline Prioritization of Next-Generation Product Candidates

Jan 4, 2023 04:10PM

Nov 30, 2022 09:55AM

Nov 10, 2022 04:10PM

Oct 3, 2022 08:01AM

Oct 3, 2022 08:00AM

Sep 26, 2022 08:01AM

Sep 26, 2022 08:00AM Celularity Publishes New Data in Frontiers in Immunology Demonstrating Placental-derived Natural Killer Cells (CYNK) Recognized and Eliminated Influenza A Virus (IAV)-infected Cells In Vitro

Aug 9, 2022 04:10PM

Jul 27, 2022 08:00AM

May 16, 2022 04:10PM

Mar 31, 2022 04:05PM

Feb 15, 2022 04:25PM

Feb 15, 2022 04:05PM

Jan 18, 2022 08:00AM Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junctio

Dec 27, 2021 09:24AM

Dec 27, 2021 09:15AM

Dec 27, 2021 08:01AM

Dec 27, 2021 08:00AM

Nov 29, 2021 08:03AM

Nov 29, 2021 08:00AM

Sep 15, 2021 08:00AM Celularity Appoints Andrew L. Pecora, M.D., F.A.C.P., C.P.E., as President

Aug 16, 2021 05:15PM

330,004 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All